Congratulations to Akesobio Pharmaceuticals for Cadonilimab (PD-1/CTLA-4) injection Approved by NMPA
- Categories:News & Events
- Author:
- Origin:
- Time of issue:2022-07-07 16:08
- Views:
(Summary description)
Congratulations to Akesobio Pharmaceuticals for Cadonilimab (PD-1/CTLA-4) injection Approved by NMPA
(Summary description)
- Categories:News & Events
- Author:
- Origin:
- Time of issue:2022-07-07 16:08
- Views:
Congratulations to Akesobio Pharmaceuticals for Cadonilimab (PD-1/CTLA-4) injection, the first market approved novel bispecific immune-oncology product by NMPA. Cadonilimab fully exploits the synergistic anti-tumor effect of two immune checkpoint inhibitors, PD-1 & CTLA-4, with significantly fewer side effects than the combination of two monoclonal antibodies with the relevant targets. At recent years, UP-Pharma has proudly provided bioanalytical supports to further expedite Akesobio ongoing clinical development studies in tumor treatment. The effective and fruitful collaboration helped the acceleration of drug development programs and bringing better medicine to patients.
Scan the QR code to read on your phone
Contact Us
Beijing Address:Tower B, No.33 Science Park Road, Changping District, Beijing, P. R. China 102206
Shanghai Address:Building 30, Lane 908, Ziping Road, Pudong New Area, Shanghai, P. R. China 201318
Tianjin Address:Building B03, Venture Headquarters, Fuyuan Road North, Wuqing Development Zone, Tianjin, P. R. China 301700
Guangxi Address:Building 3, Yunlang Science Park, Fangcheng District, Fangchenggang City, Guangxi,P. R. China 838000
Business Email:BD@up-pharma.com
Recruitment Email:hr@up-pharma.com
Copyright © 2022 United-Power Pharma Tech Co., Ltd (UPP) All Rights Reserved 京ICP备15042399号